Ip Share Discussion Threads

[bamboo2] 04/10/2022 12:30

15 September 2022


FOR RELEASE ON 15(th) September 2022

IP Group plc - Investor presentation

IP Group plc (LSE: IPO) ("IP Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, is pleased to announce that it will host an industry-wide event titled 'Technology Trailblazers: Backing Deeptech to 2030 and Beyond' on Wednesday 05 October 2022.

The IP Group Deeptech team looks forward to welcoming investors, co-investors, analysts and the wider tech ecosystem for a thought-provoking evening of talks from two of the UK's foremost technology innovators. Dr Tom Carter, decorated innovator and Founder & CEO of multi award-winning technology company Ultraleap Ltd will speak on 'The Metaverse: a playground, classroom or workplace?'. Professor Niki Trigoni, head of the University of Oxford Cyber Physical Systems Group and founder of Navenio Ltd, will speak on the topic of 'Where next for applied AI?'. In 2020 Niki won the KPMG Award for "Best British Tech Pioneer" and in 2022 she won "CTO of the Year" at the UK's Women in IT Awards.

These talks will be followed by a short panel discussion comprising the speakers alongside IP Group's Managing Partner for Technology, Dr Mark Reilly.

The event will be hybrid (both in person and virtual) and take place from 5.00pm. For further information and to register to attend, please visit the events section of our website: hxxps://www.ipgroupplc.com/events .

The online update will be hosted through the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: hxxps://www.investormeetcompany.com/ip-group-plc/register-investor . Investors who already follow IP Group plc on the Investor Meet Company platform will automatically be invited.

The in-person event will be followed by networking alongside drinks and canapes.

No material new information will be released by the Company during the presentation.

[bottomfisher] 04/10/2022 12:19

Hi Palisz. I can't find any reference to a presentation this evening on IPO's website. Do you have a link to it?

[palisz] 04/10/2022 11:46

The total lack of anything from IPO is staggering. This evening's presentation is unlikely to add anything of real value, although looks like optimism ahead has created the small rel. bounce. Really need to hear from the CEO, maybe director buys or company share buyback, something to keep the rally from fading. Not holding my breath.

[spooky] 29/9/2022 09:51

Bamboo2 - Do you have a stop loss on your position?

[p1nkfish] 28/9/2022 09:49

It would be better as a private entity, have thought so for a while, but not at this price!

[palisz] 28/9/2022 08:36

What's going on? The private equity market is seeing big mark downs in portfolios. I warned of this here and to the management many months ago. Probably explains lack of new deals. The end June NAV is a fairy tale, need to assume it's substantially lower, (well so the market says) I'm working on 100p (random dart thrown round number). Still makes the shares look cheap, but the unknown means people bailing out, although interestingly seen some nibbling. (Liontrust) Presentation next week may come with update and management comment. Again, hopefully (Never invest on hope!)

[palisz] 28/9/2022 08:22

Last year the share buyback started 8th Oct. I suspect we get a repeat sometime early October again. Hopefully!

[palisz] 28/9/2022 08:16

Down over 50% this year, back to covid lows, back to 2011 lows and below the 2003 listing.... what a fing disaster...

[bamboo2] 27/9/2022 23:29

I am worried this could become subject to a low offer.

Someone like US based Acacia would happily asset strip this down over a few years. Like they did with part of the Woodford portfolio.

[p1nkfish] 27/9/2022 23:20

Don't worry, we will know when it bottoms.
Management will award themselves share based compensation by the bucket load.

[dennisbergkamp] 27/9/2022 22:41

It’s nuts. What is going on?

D

[bamboo2] 27/9/2022 22:01

Current situation.

MCap at 59p = £609,661,553

Cash [30/6/22] 23p/sh

ONT [238p] 18.9p/sh

Cash + ONT = 41.9p/sh

Remainder = 17.1p/sh

[bamboo2] 18/9/2022 12:27

Following DNL, I have been trying to work out which of the listed flatliners will be next to fall to a bid. Certainly TRX [Tissue Regenix] and ITX [Itaconix] are possible, but there are others too.

The last few days have seen interest in ABDX [Abingdon Health].

[bamboo2] 16/9/2022 07:51

FOR RELEASE ON 15(th) September 2022

IP Group plc - Investor presentation

IP Group plc (LSE: IPO) ("IP Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, is pleased to announce that it will host an industry-wide event titled 'Technology Trailblazers: Backing Deeptech to 2030 and Beyond' on Wednesday 05 October 2022.

The IP Group Deeptech team looks forward to welcoming investors, co-investors, analysts and the wider tech ecosystem for a thought-provoking evening of talks from two of the UK's foremost technology innovators. Dr Tom Carter, decorated innovator and Founder & CEO of multi award-winning technology company Ultraleap Ltd will speak on 'The Metaverse: a playground, classroom or workplace?'. Professor Niki Trigoni, head of the University of Oxford Cyber Physical Systems Group and founder of Navenio Ltd, will speak on the topic of 'Where next for applied AI?'. In 2020 Niki won the KPMG Award for "Best British Tech Pioneer" and in 2022 she won "CTO of the Year" at the UK's Women in IT Awards.

These talks will be followed by a short panel discussion comprising the speakers alongside IP Group's Managing Partner for Technology, Dr Mark Reilly.

The event will be hybrid (both in person and virtual) and take place from 5.00pm. For further information and to register to attend, please visit the events section of our website:

.

The online update will be hosted through the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via:

.

Investors who already follow IP Group plc on the Investor Meet Company platform will automatically be invited.

The in-person event will be followed by networking alongside drinks and canapes.

No material new information will be released by the Company during the presentation.

[bamboo2] 14/9/2022 17:36

Afaik, the co. is planning to change the rules at the next opportunity [AGM?] to allow interim dividends to be 'paid' from Treasury shares, instead of diluting all.

==================================

FOR RELEASE ON 14 September 2022

IP Group plc - Further re Scrip Dividend

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces that, further to the announcements dated 03 August 2022, 18 August 2022 and 13 September 2022 in connection with the Interim Scrip Dividend, the Group has received valid elections from shareholders resulting in a requirement to issue 154,718 new ordinary shares of 2p each ("New Shares").

An application has been made for the New Shares to be issued in connection with the Scrip Dividend to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange respectively.

Admission of the New Shares is expected to be effective on 20 September 2022. Following admission and in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Group will have 1,063,188,005 Ordinary Shares in issue and 28,607,622 Ordinary Shares in Treasury.

The total number of Ordinary Shares with voting rights following the issue of the New Shares will be 1,034,580,383 Ordinary Shares. This figure may be used by shareholders in the Group as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Group under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

[oakville] 12/9/2022 11:22

IPO has a basket full of exciting investments. Bought in this morning having done due diligence over the weekend.

[bamboo2] 11/9/2022 10:40

Missed this report a few months ago.

Bucking the economic downturn, Hinge Health charts strong growth, stretching its reach in the employer MSK market By Heather Landi Jul 14, 2022



U.S. healthcare faces a massive and expensive problem that has become a big pain in the neck (pun intended) for workers and employers alike.

One in two Americans experiences back, neck, shoulder or other musculoskeletal (MSK) pain in any given year. MSK remains one of the top three cost drivers in the U.S. health system—consuming 1 in 6 healthcare dollars for large employers and $600 billion for the U.S. economy overall, according to a report that sources data from the Centers for Disease Control and Prevention as well as the National Health Interview Survey.

In response to demand, the digital MSK market is booming, and employers are doubling down on solutions to address employees' chronic pain issues. Only 10% of employers currently have a MSK solution, according to a 2020 Business Group on Health employer survey, but 70% of employers plan to adopt a digital MSK solution in the next two years.

Launched just seven years ago, Hinge Health has capitalized on soaring demand for virtual MSK and physical therapy services. More than $1 billion has been invested in the company, including a $400 million financing round in October backed by investors Coatue and Tiger Global. At a valuation of $6.2 billion, Hinge Health is now one of the most valuable startups in digital health.

The San Francisco-based startup is on track to sign up more customers for its digital MSK clinic in 2022 than in the past seven years combined, co-founder and CEO Daniel Perez told Fierce Healthcare in an exclusive interview about the company's growth.

As Americans accelerated digital healthcare adoption during the pandemic in 2020, Hinge Health’s customer base tripled and revenue quadrupled, the company reported.

In an interview with Fierce Healthcare in January 2021, co-founder Gabriel Mecklenburg confirmed Hinge Health was eyeing a potential initial public offering in 2022.

"It’s one of the options on the table," Mecklenburg said. "We have enough cash on the table not to need additional funding. Three hundred million dollars is larger than the average IPO, and having access to that capital in the private market gives us a lot of agility. That being said, we're evaluating different options: direct listing, SPAC (special purpose acquisition company) and an IPO. There will be a time when we will want to go public."

Perez declined to discuss any IPO plans, acknowledging that the current market is challenging for technology companies.

"We're just focused on building the business right now. We think it's a great opportunity to keep our heads down and build the business," he said.

The company is not yet profitable but has a "clear path" to profitability, he noted.


Booming demand for MSK solutions

The current challenging economic conditions actually have been fueling Hinge Health's employer-based business as companies look to tackle employee healthcare costs with greater urgency, he said.

"A lot of business leaders are facing a twin problem. On one side, there's obviously inflation and uncertain economic climates but there still remains pretty darn intense competition for talent. That's caused a lot of companies to turn to Hinge because we're able to both help them reduce their costs, which is quite relevant in a period of austerity, and also help them attract and retain talent by improving the health of their existing employees," he said.

MSK pain has a widespread impact across job types and nearly every industry—with prolonged standing at work, sedentary working, repetitive tasks and manual labor all significant risk factors.

Large, self-insured employees are paying for every dollar of their employees' healthcare costs. "Many business executives are starting to look at, in these periods of austerity, do we have a lot of avoidable healthcare costs? What they are seeing is, overwhelmingly, their musculoskeletal costs are being driven by elective surgeries that can be avoidable," he said.

Hinge Health now works with more than 750 employers and is on track to add more later this year. Major new customers include industry leaders across the e-commerce, home improvement, technology and automotive sectors as well as many retirement and state health systems. Hinge Health continues to be the choice of 4 in 5 employers and nearly 9 in 10 health plans, Perez said.

Investing in tech

Co-founders Mecklenburg and Perez both have a personal history of MSK injuries and started Hinge Health to improve outcomes for MSK disorders.

Perez broke several bones in a biking accident when he was younger and underwent 12 months of rehab. Mecklenburg also suffered an MSK injury, tearing his ACL during a judo sparring session. They both saw firsthand the inefficiencies in accessing care in the traditional way. Perez met Mecklenburg in the U.K. when he was pursuing his Ph.D. in biochemistry.

"We both realized that when it comes to MSK issues there is a really good evidence base for what nonsurgical, non-opioid care is but that it's very inefficient and difficult to deliver. We thought we could use technology to simply better deliver the evidence base and eventually use technology to go beyond the evidence base," Perez said.

Research has shown conservative management care that combines physical therapy, patient education and lifestyle modifications can help avoid two out of three elective surgeries, he said. Often, financial incentives in the healthcare system drive more invasive procedures, he noted.

Hinge Health sees itself as going beyond digital physical therapy, which itself is a growing market.

"We have taken best practice guidelines, nonsurgical and non-opioid care for back and joint pain, and use technology to better deliver it for exercise therapy, education and behavioral health support," he said.

Hinge Health developed a digital MSK clinic that offers a complete clinical care model for back and joint pain with dedicated programs for different patients' needs from early-stage prevention, acute pain, chronic pain or surgical rehabilitation.

The company's solution pairs advanced wearable sensors and computer vision technology with a comprehensive clinical care team of physical therapists, physicians and board-certified health coaches. The company's computer vision and motion sensors aid patients with exercise therapy and motion assessments.

Hinge has made big investments in technology both through internal R&D to bolster its artificial intelligence, machine learning and computer vision capabilities and through acquisitions.

"We now have the world's most sophisticated computer vision models to where now we can use just the camera on somebody's phone or the camera on their laptop to be able to capture their movement in space with higher fidelity than the human eye in capturing about nearly 90 different points on the human body. It's accurate as Hollywood motion picture labs to be able to capture people in their own home," Perez said.

The company picked up medical device maker Enso to expand its musculoskeletal therapy solutions. Enso's device works by delivering a patented electrical stimulation treatment that relaxes the muscles and calms the nerves and is controlled via an app on smartphones.

Focusing on ROI and expanding solutions

According to Perez, the company pioneered using sensor technology combined with physical therapy and health coaches to drive strong clinical outcomes.

In a large-scale study published in 2020, researchers at Stanford, UCSF and Vanderbilt found that patients who used Hinge Health's program had an average pain reduction of 69%, reduced depression and anxiety of 58% and decreased surgery likelihood of 67%. Participants had a 73% completion rate with the program.

In the industry’s largest study to date, an analysis across 136 employers found $2,387 cost savings per participant for employers who provided the company’s digital MSK Clinic.

A study published this year demonstrated financial benefits of Hinge Health's digital MSK care for older adults. The study, based on medical claims analysis using Medicare enrollment and claims data under Medicare Parts A and B, showed a 2.7x return on investment for Medicare driven by statistically significant reductions in medical-service use and annual healthcare savings of $2,655 per participant compared to a control group.

"We look at MSK a bit more nuanced than I think other folks do. There's low risk, medium risk and high risk, and I think we're the only digital musculoskeletal solution that comes with a full comprehensive care team to also address employers' high-risk members," Perez said.

About 1% of members drive 55% to 60% of MSK cost, he said. "If you don't actually address the high-risk members, you won't actually reduce costs."

The company has significantly invested in bridging the gap between digital and in-person care to make it seamless for the end user. Its HingeConnect technology integrates with electronic medical records systems across nearly 1 million providers over 100,000 care sites. "This allows us to know in near real time if a member were to be seen by a surgeon or about to go to surgery or be prescribed opiates, and we can proactively offer them nonsurgical alternatives for their back pain or knee pain," Perez said.

The company also recently launched a women's pelvic health program to help address the 1 in 4 women with a pelvic floor disorder.

"We're continuing to invest in differentiation. In any sort of market pullback, the market leader, which Hinge Health is, needs to be appropriately cautious, but also appropriately aggressive. We're hopeful that we're striking the right balance between the two," Perez said.

[bamboo2] 11/9/2022 09:40

Investment business IP Group has announced that it is set to receive approximately £14m in cash from the sale of its shareholding in Diurnal Group.

Yesterday, it was announced that an offer of 27.5 pence in cash for each Diurnal share by Neurocrine, a US-headquartered neuroscience-focused, biopharmaceutical company, has been recommended to shareholders.

The Cardiff-based company's board has been advised on the terms of the deal - which values Diurnal at about £48.3m - by investment bank Panmure Gordon.

IP Group has a holding of 29.4 per cent in Diurnal.

The acquisition is conditional on the approval of Diurnal shareholders, among other things.

Diurnal Group is focused on patient needs in chronic endocrine (hormonal) diseases.

The business, which employs 33 staff, has a portfolio which includes approved treatments for paediatric adrenal insufficiency (AI) and congenital adrenal hyperplasia.

[oakville] 07/9/2022 07:53

TRX results are decent.

[p1nkfish] 06/9/2022 11:31

Hysata for hydrogen a day I think another portfolio company was working on greener aero fuels but that might be flaky memory.

[bamboo2] 05/9/2022 22:13

This has to help Hinge Health's valuation.

================================================

CVS Health has reached a deal to acquire in-home health-care company Signify Health for about $8 billion, the companies said Monday.

CVS said it will pay $30.50 a share in cash for Signify, an acquisition that would build on its growing health-care services. Signify provides technology and analytics to help with in-home patient care.

“This acquisition will enhance our connection to consumers in the home and enables providers to better address patient needs as we execute our vision to redefine the health care experience,” CVS Health President and CEO Karen Lynch said in a news release.

The deal comes as competitors from Amazon to Walgreens are moving further into the health-care sector. In July, Amazon announced it was acquiring primary-care provider One Medical for about $3.9 billion.

Signify Health’s shares have surged nearly 45% over the last month to give it a market value of about $6.7 billion at $28.77 a share as of Friday’s close, according to FactSet. The Wall Street Journal reported on Aug. 2 that Signify was exploring strategic alternatives, including a sale.

Shares of Signify, which went public in February 2021, surged in late August after reports that Amazon was among the bidders.

Last month, CVS revealed plans to acquire or take a stake in a primary-care company by year’s end.

The Signify deal follows other acquisitions and shifts into primary health care. CVS previously acquired insurer Aetna and pharmacy benefits manager Caremark, and customers can get vaccines or urgent care at MinuteClinic outposts inside of its stores. It recently introduced therapy for mental health at some stores.

The companies expect the acquisition, which is subject to regulatory approval, to close in the first half of next year.

Private equity firm New Mountain Capital owns about 60% of Signify’s common stock and agreed to support the deal, the companies said.

CVS Health and Signify Health will hold an analyst and investor call at 8:30 a.m. ET on Tuesday to discuss the transaction.

[bamboo2] 05/9/2022 09:42

Fishing around in the calm waters of the listed flatliners has been quite profitable for me over the years. DNL is the latest, but I am now cashed out of that one.

Looking at those that have already made bases, two that stand out with potential are ITX and TRX. Like DNL, both are possible takeover targets.

ITX had news today, an extension of the agreement with Croda.
TRX updates interims and outlook tomorrow.

edit, TRX results are in fact 7/9/2022

==================================================

Quite a number of the private listed co's are required to submit latest accounts to govt website by end of sept 2022. This sometimes provides useful info

edit, 6/9/2022, Istesso filed figs [up to 31/12/2022] today, being processed.

[edwardt] 02/9/2022 12:55

In for some too